Tamsulosin Hydrochloride Capsule
Product Images NDC 50090-6700

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 50090-6700). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906700)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by A-S Medication Solutions, Libertyville, IL. The label includes dosing instructions to see the package insert, storage conditions to store at 68 to 77 degrees Fahrenheit and avoid excessive moisture, and bottle quantity of 90 capsules. The product NDC is 50090-6700.*

FDA Label Image

Figure (Tamsulosin Fig1)

Line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over time following a single 0.4 mg dose administered as capsules under fasted and fed conditions. The x-axis represents time in hours up to 36 hours, and the y-axis shows plasma concentration in ng/mL up to 25. Two lines distinguish fasted (dashed) and fed (solid) states, illustrating concentration changes over time for eight subjects.*

FDA Label Image

Figure (Tamsulosin Fig2)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' comparing symptom score changes over treatment duration (weeks). It shows mean changes for three treatments: 0.8 mg, 0.4 mg, and placebo, with symptom scores decreasing more for the 0.8 mg and 0.4 mg groups than placebo over up to 13 weeks.*

FDA Label Image

Figure (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing changes over 13 weeks of treatment. The x-axis represents the duration of treatment in weeks, and the y-axis shows mean change. The graph compares three groups: 0.8 mg dose, 0.4 mg dose, and placebo, with the treatment groups showing greater mean reductions over time compared to placebo.*

FDA Label Image

Figure (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec on the vertical axis and duration of treatment in weeks on the horizontal axis. The graph compares three treatments: 0.8 mg, 0.4 mg of Tamsulosin Hydrochloride, and placebo over approximately 13 weeks, with mean values plotted at multiple time points. Both Tamsulosin doses show an increase in peak urine flow rate compared to placebo, which remains low throughout the study.*

FDA Label Image

Figure (Tamsulosin Fig5)

A line graph depicting mean increase in peak urine flow rate (mL/sec) over a treatment duration of up to 13 weeks, comparing Tamsulosin Hydrochloride at 0.8 mg and 0.4 mg doses with placebo. The graph shows treatment response measured at multiple time points, with separate lines for each dose and placebo.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing molecular composition with rings, functional groups including methoxy, sulfonamide, and hydrochloride components as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.